Assessment of biochemical recurrence of prostate cancer (Review)
Open Access
- 4 October 2019
- journal article
- review article
- Published by Spandidos Publications in International Journal of Oncology
- Vol. 55 (6) , 1194-1212
Abstract
The assessment of the risk of biochemical recurrence (BCR) is critical in the management of males with prostate cancer (PC). Over the past decades, a comprehensive effort has been focusing on improving risk stratification; a variety of models have been constructed using PC‑associated pathological features and molecular alterations occurring at the genome, protein and RNA level. Alterations in RNA expression (lncRNA, miRNA and mRNA) constitute the largest proportion of the biomarkers of BCR. In this article, we systemically review RNA‑based BCR biomarkers reported in PubMed according to the PRISMA guidelines. Individual miRNAs, mRNAs, lncRNAs and multigene panels, including the commercially available signatures, Oncotype DX and Prolaris, will be discussed; details related to cohort size, hazard ratio and 95% confidence intervals will be provided. Mechanistically, these individual biomarkers affect multiple pathways critical to tumorigenesis and progression, including epithelial‑mesenchymal transition (EMT), phosphatase and tensin homolog (PTEN), Wnt, growth factor receptor, cell proliferation, immune checkpoints and others. This variety in the mechanisms involved not only validates their associations with BCR, but also highlights the need for the coverage of multiple pathways in order to effectively stratify the risk of BCR. Updates of novel biomarkers and their mechanistic insights are considered, which suggests new avenues to pursue in the prediction of BCR. Additionally, the management of patients with BCR and the potential utility of the stratification of the risk of BCR in salvage treatment decision making for these patients are briefly covered. Limitations will also be discussed.Keywords
This publication has 287 references indexed in Scilit:
- Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohortBritish Journal of Cancer, 2012
- RNA-seq analysis of prostate cancer in the Chinese population identifies recurrent gene fusions, cancer-associated long noncoding RNAs and aberrant alternative splicingsCell Research, 2012
- A ceRNA Hypothesis: The Rosetta Stone of a Hidden RNA Language?Cell, 2011
- The CAPRA‐S scoreCancer, 2011
- Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective studyThe Lancet Oncology, 2011
- The transcription factor PlagL2 activates Mpl transcription and signaling in hematopoietic progenitor and leukemia cellsLeukemia, 2011
- PLAGL2 Regulates Wnt Signaling to Impede Differentiation in Neural Stem Cells and GliomasCancer Cell, 2010
- Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesisLaboratory Investigation, 2008
- Metallothionein 1G acts as an oncosupressor in papillary thyroid carcinomaLaboratory Investigation, 2008
- Gene expression analysis of prostate cancersMolecular Carcinogenesis, 2002